A significant shift is gathering momentum in the Life Sciences and Healthcare industry. Return on investment from late‐stage pipelines in Big Pharma is at an all‐time low. The pressure to increase returns is driving a sharpened focus on reducing time to market. Faster drug development is being enabled through advances in data capture and analytics.
A selection of articles, reports and other content.